Particularly, mutations in epigenetic modifiers, such as TET2 and DNMT3A and TP53, are common across a spectrum of clonal hematopoietic disorders, such as CHIP, clonal cytopenias, MDS and AML-MRC [36]. This evidence concerns the gene TP53 and myelodysplastic syndrome.